Late Hypothermia for Hypoxic-Ischemic Encephalopathy

NICHD Neonatal Research Network

Status

Completed

Conditions

Infant, Newborn

Ischemic-Hypoxic Encephalopathy

Hypoxia-Ischemia, Brain

Hypoxic-Ischemic Encephalopathy

Hypoxia, Brain

Encephalopathy, Hypoxic-Ischemic

Treatments

Procedure: Hypothermia

Procedure: Normothermic Control

Study type

Interventional

Funder types

NETWORK

NIH

Identifiers

NCT00614744

U10HD053109 (U.S. NIH Grant/Contract)

UL1RR024979 (U.S. NIH Grant/Contract)

U10HD068270 (U.S. NIH Grant/Contract)

1U10HD068263-01 (U.S. NIH Grant/Contract)

U10HD021364 (U.S. NIH Grant/Contract)

U10HD027880 (U.S. NIH Grant/Contract)

U10HD027856 (U.S. NIH Grant/Contract)

U10HD036790 (U.S. NIH Grant/Contract)

U10HD053089 (U.S. NIH Grant/Contract)

U10HD027851 (U.S. NIH Grant/Contract)

U10HD068244 (U.S. NIH Grant/Contract)

NICHD-NRN-0038

U10HD040689 (U.S. NIH Grant/Contract)

U10HD068278 (U.S. NIH Grant/Contract)

U10HD027871 (U.S. NIH Grant/Contract)

UL1RR024139 (U.S. NIH Grant/Contract)

U10HD021373 (U.S. NIH Grant/Contract)

U10HD027853 (U.S. NIH Grant/Contract)

U10HD053119 (U.S. NIH Grant/Contract)

UL1RR025744 (U.S. NIH Grant/Contract)

U10HD040492 (U.S. NIH Grant/Contract)

U10HD053124 (U.S. NIH Grant/Contract)

U10HD068284 (U.S. NIH Grant/Contract)

U10HD034216 (U.S. NIH Grant/Contract)

U10HD021385 (U.S. NIH Grant/Contract)

U10HD027904 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This study is a randomized, placebo-controlled, clinical trial to evaluate whether induced whole-body hypothermia initiated between 6-24 hours of age and continued for 96 hours in infants ≥ 36 weeks gestational age with hypoxic-ischemic encephalopathy will reduce the incidence of death or disability at 18-22 months of age. The study will enroll 168 infants with signs of hypoxic-ischemic encephalopathy at 16 NICHD Neonatal Research Network sites, and randomly assign them to either receive hypothermia or participate in a non-cooled control group.

Full description

Hypoxic-ischemic encephalopathy (HIE) is a rare, but life-threatening condition characterized by acute or subacute brain injury due to asphyxia. In most cases the underlying cause and timing of injury are unknown, but many cases are diagnosed at or shortly after birth.

According to the World Health Organization, more than 722,000 children died from birth asphyxia and birth trauma worldwide in 2004. An estimated 50-75 percent of infants with severe (stage 3) HIE will die, with 55 percent of these deaths occurring in the first month.

The incidence of long-term complications depends on the severity of HIE. Up to 80 percent of infants who survive stage 3 HIE develop significant long-term neurological disabilities - mental retardation, epilepsy, and cerebral palsy with hemiplegia, paraplegia, or quadriplegia; 10-20 percent develop moderately serious disabilities; and up to 10 percent are normal.

Because animal data suggests that brain injury from HIE evolves over several hours to days after the initial asphyxic insult, induced hypothermia holds promise as a neuroprotective therapy. Additional trials are needed to help define the most effective cooling strategies.

With this in mind, and knowing that many babies with HIE arrive at neonatal intensive care units several hours after birth, this study will evaluate the safety and efficacy of initiating hypothermia 6-24 hours after birth.

Study subjects: Infants born at 36 0/7ths weeks or greater gestational age that have been diagnosed with neonatal depression, perinatal asphyxia, or encephalopathy. The goal is to enroll 168 subjects.

Stratification: After informed consent is obtained, infants will be randomized to either a hypothermia arm (with a target esophageal temperature of 33.5°C) or a control arm (37.0°C) for 96 hours. Enrolled infants will be stratified by age of enrollment (≤ 12 and > 12 hours) and stage of encephalopathy (moderate or severe).

Informed Consent: Parents of eligible infants will be approached for consent to enroll in the study if the infant has a high probability of acute hemodynamic compromise, as defined above. Subsequent screening will determine whether the infant meets all inclusion criteria.

Randomization: eligible and consented infants will be randomly assigned to either a hypothermia intervention group, or a non-cooled (control) group.

Study Intervention: Induced whole-body hypothermia (with a target esophageal temperature of 33.5°C) or a control group (37.0°C) for 96 hours.

Interim Study Interruptions: None to date.

Secondary Study includes determining an association between MRI detectable injury and neurodevelopment at 18-22 months.

Enrollment

168 patients

Sex

All

Ages

6 to 24 hours old

Volunteers

No Healthy Volunteers

Inclusion criteria

Infants born at 36 0/7ths weeks gestational age or greater (by best obstetrical estimate)
Postnatal age between 6 and 24 hours following birth
Infants with a high probability of acute hemodynamic compromise, such as those with:
- An acute perinatal event (abruptio placenta, cord prolapse, severe FHR abnormality)
- An Apgar score ≤ 5 at 10 minutes
- Continued need for ventilation initiated at birth for at least 10 minutes
- Cord pH or first postnatal blood gas pH at ≤ 1 hour of ≤ 7.0
- Base deficit on cord gas or first postnatal blood gas at ≤ 1 hour of ≥ 16 mEq/L
Infants matching the above criteria who also have an abnormal neurological exam showing the presence of moderate or severe encephalopathy
Infants whose parents/legal guardians have provided consent for enrollment.

NOTE: These inclusion criteria are identical to the NICHD Neonatal Research Network's 2005 Hypothermia study (see links below), except for the time of entry (6-24 hours vs. < 6 hours of age).

Exclusion criteria

Any infant with a core body temperature (axilla, rectal) less than 34.0°C for greater than 1 hour
Presence of a known anomaly or chromosomal aberration
Birth weight < 1,800 grams
Infant in extremis
Infants whose parents/legal guardians or attending physician refuse consent